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Abstract
Introduction: Metabolic syndrome (MS), which is connected with enlarged cardiovascular risk, is common in patients with OSAS.
The aim of the study was to estimate the prevalence of MS in patients with OSAS according to two definitions of MS (criteria 
from NCEP-ATP III from 2001 versus criteria from IDF 2005).
Material and methods: Materials consisted of 155 males and 18 females with OSAS (mean AHI 44 ± 22 h-1), obesity (BMI 31.8 
± 5.0 kg/m2), aged 53.9 ± 9.3 years (mean ± SD). Serum lipids, glucose, body mass index (BMI), waist circumference (WC) 
and waist-to-hip ratio (WHR) were measured in all patients.
Results: According to first definition (NCEP — ATP III from 2001), MS was diagnosed in 98 patients (56% of the whole group — 
MS1 group) compared to 120 patients (69% of the whole group — MS2 group) diagnosed according to the second definition (IDF 
from 2005), p < 0.05. No differences in BMI and WC between the groups were found. Significant differences in WHR were noted 
(MS1 group: 1.005 ± 0.05 vs. MS2 group: 1.027 ± 0.06, p < 0.05). Patients from the MS2 group had higher cholesterol HDL 
compared to the MS1 group (52.3 ± 12.1 mg/dl vs. 42.3 ± 12.1 mg/dl, p < 0.05). Serum triglyceride concentrations were signifi-
cantly higher in the MS1 group than in the MS2 group (228 ± 122 mg/dl vs. 122 ± 49 mg/dl, p < 0.05). There were no differences 
in OSAS severity between the MS1 and MS2 group. In both groups weak correlations between diagnosis of MS and AHI were f 
ound (r = 0.19 for MS1 and r = 0.21 for MS2, p < 0.05) They are, however, clinically insignificant.
Conclusions: The IDF definition from 2005 of metabolic syndrome indeed increases the frequency of diagnosis of metabolic syn-
drome in patients with OSAS. We did not observe essential clinical correlation among the degree of OSAS severity and recognition 
of metabolic syndrome in the MS1 or in the MS2 group.
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Streszczenie
Wstęp: Zespół metaboliczny (ZM) jest związany ze zwiększonym ryzykiem chorób sercowo-naczyniowych i występuje często 
u chorych na OBS.
Celem pracy jest cena częstości ZM w zależności od zastosowanej definicji (NCEP-ATP III z 2001 oraz IDF z 2005 roku) u chorych na OBS. 
Materiał i metody: Materiał stanowiło 155 mężczyzn i 18 kobiet z OBS (AHI 44 ± 22 h-1), w większości otyłych (BMI 31,8 ± 5,0 kg/m2), 
w wieku 53,9 ± 9,3 roku (średnie ± SD).
U badanych oznaczano w surowicy: lipidogram, stężenie glukozy oraz wykonano pomiar wskaźnika masy ciała (BMI), obwodu 
w pasie (OP) oraz wskaźnik talia-biodra (WHR). 
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Wyniki: Posługując się definicją pierwszą (NCEP-ATP III z 2001), zespół metaboliczny rozpoznano u 98 chorych (56% całej grupy 
— grupa ZM1), stosując definicję IDF z 2005 — u 120 osób (69% całej grupy — grupa ZM2) (p < 0,05). Pomiędzy grupami nie 
stwierdzono istotnych różnic wielkości BMI i OP. Natomiast statystycznie istotną różnicę stwierdzono w WHR (ZM1: 1,005 ± 0,05 
v. ZM2: 1,027 ± 0,06, p < 0,05). W grupie ZM2 stwierdzono istotnie wyższe stężenie HDL w porównaniu z grupą ZM1 (52,3 ± 
12,1 mg/dl v. 42,3 ± 12,1 mg/dl, p < 0,05). W grupie ZM1 istotnie wyższe w porównaniu z grupą ZM2 było stężenie triglicerydów 
w surowicy (228,2 ± 122,5 mg/dl v. 122,5 ± 49,1 mg/dl, p < 0,05). Grupy ZM1 i ZM2 nie różniły się istotnie stopniem ciężkości 
OBS. Zaobserwowano korelacje pomiędzy rozpoznaniem zespołu metabolicznego a wartością AHI (r = 0,19 dla ZM1 i r = 0,21 
dla ZM2, p < 0,05). Są one jednak klinicznie nieistotne.
Wnioski: Definicja zespołu metabolicznego IDF z 2005 roku istotnie zwiększa częstość rozpoznawania zespołu metabolicznego 
u  chorych na OBS. Nie zaobserwowano znamiennych klinicznie korelacji pomiędzy stopniem ciężkości OBS a  rozpoznaniem 
zespołu metabolicznego. 
Słowa kluczowe: definicja, zespół metaboliczny, obturacyjny bezdech senny
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Introduction
Metabolic syndrome (MS) is a  significant 
cause of development of cardiovascular system 
diseases and type 2 diabetes [1]. It doubles the 
risk of cardiovascular diseases and increases the 
risk of development of type 2 diabetes by five 
times [2]. Several definitions of this syndrome 
have been elaborated in recent years. In the 
USA in 2001 the Third Report of the National 
Cholesterol Education Program Expert Panel on 
Detection, Evaluation and Treatment of High 
Blood Cholesterol in Adults (NCEP-ATP III) 
used for the first time clinical aspects in the 
definition of metabolic syndrome [3]. According 
to the NCEP-ATP III criteria, diagnosis of MS 
is based on the occurrence of at least three out 
of five components of the syndrome, such as: 
elevated fasting plasma glucose (or previously 
diagnosed type 2 diabetes), abdominal obesity 
measured by waist circumference, elevated 
triglycerides, decreased HDL-cholesterol and 
increased arterial blood pressure (Table 1). In 
2005 the International Diabetes Federation (IDF) 
proposed a new definition (Table 1) based on the 
assumption that the presence of abdominal obe-
sity and, additionally, two out of four remaining 
components, as defined in the NCEP-ATP III 
definition, are necessary conditions for the dia-
gnosis of metabolic syndrome. While evaluating 
abdominal obesity the IDF definition considers 
racial and ethnic factors and assumes different 
criteria for the European and for the Asian popu-
lation (except for the Japanese) [4]. A value over 
100 mg% was assumed as impaired fasting pla-
sma glucose, and it was also assumed that pa-
tients treated for dyslipidaemia, hyperglycaemia 
or type 2 diabetes and arterial hypertension meet 
criteria for diagnosis of metabolic syndrome.
In 2005 the American Heart Association (AHA) 
and National Heart, Lung and Blood Institute 
(NHLBI) took into account the position of IDF and 
presented the modified NCEP-ATP III definition 
of 2001 [5]. It took into consideration recommen-
dations of IDF concerning ethnic differences and 
distinguished separate criteria for obesity for people 
of American or Asian origin. A value over 100 mg% 
was also assumed as impaired fasting glycaemia, 
and the possibility of diagnosis of metabolic syn-
drome was also allowed in patients with dyslipi-
daemia, hyperglycaemia or arterial hypertension. 
The main difference between the NCEP-ATP III and 
IDF definitions was still an obligatory incidence of 
abdominal obesity in the latter (Table 1). 
In 2009 the IDF, NHLBI, AHA, World Heart 
Federation (WHF), International Atherosclerosis 
Society (IAS) and International Association for 
the Study of Obesity (IASO) published a common 
statement concerning the definition of metabolic 
syndrome [6]. Consensus among the organizations 
assumed that in order to diagnose metabolic 
syndrome three out of five previous IDF criteria 
would be sufficient, without the necessity of obe-
sity perceived as a main criterion. This definition 
is presently recommended and used.
In 1998 Wilcox attached metabolic syndrome 
(syndrome X) to OSAS and created the notion 
of syndrome Z  [7]. Metabolic syndrome occurs 
from 5 to 9 times more frequently in patients 
with OSAS than in control groups [8, 9], and its 
prevalence varies from 19% among the snoring 
population in Korea to 87% of patients with OSAS 
in Great Britain [10]. The majority of studies re-
port that the prevalence of metabolic syndrome 
in patients with OSAS reaches 30–77% and it in-
creases together with severity of OSAS [8, 11–15]. 
Many researchers [10] showed an independent re-
lation between OSAS and hyperinsulinaemia and 
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lipid metabolism disorders. Most of them show 
a significant correlation between Apnea-Hypop-
nea Index (AHI) and the occurrence of metabolic 
syndrome; however, such a relationship was not 
observed between transient hypoxaemia and MS 
[10, 16]. Due to the fact that AHI in patients with 
OSAS correlates with visceral fat tissue more 
strongly than with BMI, it was suggested that obs-
tructive sleep apnoea was an element of metabolic 
syndrome [17]. One of the studies demonstrated 
that symptoms such as loud snoring and excessive 
daytime sleepiness may be predictors of deve-
lopment of metabolic syndrome, and OSAS is its 
inherent element [18]. Therefore, an appropriate 
definition of metabolic syndrome used for early 
diagnosis and treatment of MS in patients with 
OSAS seems to be a significant clinical problem. 
The aim of this study was to assess the 
prevalence of metabolic syndrome in patients 
with OSAS depending on the applied definition 
of MS (the one formulated by the NCEP-ATP III 
in 2001 or that specified by the IDF in 2005), and 
to try to evaluate which of them correlates better 
with OSAS severity, and which one is a better 
clinical tool to diagnose metabolic syndrome in 
this group of patients.
Material and methods
The examined group was selected from the 
patients of the Clinic of Sleep-Disordered Bre-
athing in the Autonomous Public Clinical Ho-
spital in Warsaw. All patients gave consent to 
their participation in the research. Additionally, 
a physical examination consisted of measurement 
of waist-to-hip ratio with the use of standard me-
thod, i.e. measurement of waist circumference (in 
centimetres) in half the distance between the lo-
wer edge of the ribs and the upper iliac crest, and 
hip circumference (in centimetres) indicating the 
widest measurement at the height of the greater 
trochanter [19]. Based on these two values, the 
waist-to-hip ratio (WHR) was defined. The degree 
of obesity was determined by body mass index 
(BMI) according to the WHO classification [20]. 
Metabolic syndrome was diagnosed pursuant to 
the NCEP-ATP III definition of 2001 and the IDF 
definition of 2005 [3, 4].
Diagnostics of OSAS
A polysomnography test (PSG) was executed 
with the help of Alice 4 apparatus from RESPI-
RONICS, USA. After the test, qualified laboratory 
staff verified the results of the automatic analysis 
by using the software supplied by the producer.
The tests were conducted between 11 p.m. and 
6 a.m. the following day, in a soundproof room. 
They were supervised by a physician or a trained 
student of the faculty of medicine of the Medical 
University of Warsaw. OSAS was diagnosed based 
on the criterion defined in the report of the Ameri-
can Academy of Sleep Medicine (AASM) [21], i.e. 
total apnoea-hypopnoea index (AHI) ≥ 5 episodes 
of breathing disorders during one-hour sleep in 
the case of typical symptoms of OSAS, or ≥ 15 epi-
sodes of breathing disorders during sleep without 
characteristic of ailments of this disease. A total 
of 155 men and 18 women with mean age 53.9 ± 
9.3 years were examined, with AHI 44.3 ± 22.1 h-1 
and BMI 31.8 ± 5.0 kg/m2. Arterial hypertension 
was diagnosed in 94 patients, 53 were treated for 
dyslipidaemia and 13 for type 2 diabetes.
Table 1. Definitions of metabolic syndrome (NCEP-ATP III i IDF)
Definition of MS NCEP-ATP III 2001
Presence of ≥ 3 of the following: 
IDF 2005
WC above the presented limit plus any 2  
of the following: 
Abdominal obesity WC:
F: ≥ 88 cm
M: ≥ 102 cm
WC:
F: ≥ 80 cm
M: ≥ 94 cm
Triglycerides  ≥ 150 mg% (1.7 mmol/l)  ≥ 150 mg% (1.7 mmol/l) or taking medication  
for lipid disorder
HDL-C  HDL-C
F: < 50 mg/dl (1.03 mmol/l)
M: < 40 mg/dl (1.29 mmol/l) 
HDL-C 
F: < 50 mg/dl (1.03 mmol/l)
M: < 40 mg/dl (1.29 mmol/l) 
or taking medication for lipid disorder
High blood pressure (BP) BP ≥ 130/ ≥ 85 mm Hg BP ≥ 130/ ≥ 85 mm Hg or diagnosis  
of hypertension
Fasting plasma glucose (FPG) FPG ≥ 110 mg/dl (≥ 6.1 mmol/l) FPG ≥ 100 mg/dl (≥ 5.6 mmol/l) or diagnosis  
of diabetes type 2
F — female, M — male; abbreviations in the text
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In order to determine glucose and lipidogram, 
all examined patients had fasting venous blood 
samples taken after a full night’s rest. Determina-
tions were taken in the Central Laboratory of the 
Autonomous Public Clinical Hospital in Warsaw 
using suitable methods.
Statistical analysis
Statistical analysis of the obtained data was 
made with the help of the program StatSoft, Inc. 
(2007) STATISTICA (data analysis software sys-
tem), version 8.0. www.statsoft.com. To compare 
independent groups, due to the parameter values 
that assume rank or nominal values, non-parametric 
Mann-Whitney U tests were employed. The tables 
include the values concerning nominal variables, 
given as mean ± SD (standard deviation). Relations 
between two nominal or rank variables, or between 
one nominal and a second ordinal value, were cal-
culated with the use of Spearman’s rank correlation. 
When two variables were qualitative or binary, 
Chi-square contingency table analysis was applied, 
and in a special case for the table 2 × 2 (consisting 
of two rows and two columns) depending on cal-
culated expected values, a version of this test with 
McNemar’s alteration was used. In order to define 
the compatibility of the two definitions of metabolic 
syndrome, the Kappa coefficient was calculated.
Results
Based on the first definition (NCEP-ATP III 
of 2001), metabolic syndrome was diagnosed in 
98 patients (56% of the whole group — the MS1 
group) in comparison to 120 patients (69% of the 
whole group — the MS2 group) diagnosed accor-
ding to the IDF definition of 2005, p < 0.05. The 
value of the Kappa coefficient at the level of 0.71 
proves the high compatibility of the two methods, 
and a significant result of McNemar’s  test, i.e. 
p < 0.001, suggests that these definitions assess 
the prevalence of metabolic syndrome in a diffe-
rent way. All criteria of the NCEP-ATP III were met 
by 10 out of 98 patients (10.2%) and in the case 
of the IDF definition — by 26 out of 120 patients 
(21.7%) (Fig. 1). The most frequent criterion was 
abdominal obesity: in the case of the NCEP-ATP III 
definition it was diagnosed in 90 out of 98 patients 
(91.8%). In the IDF definition it is an obligatory 
criterion. The most frequent among the four rema-
ining criteria was hypertriglyceridaemia (in 104 
out of 120 patients — 86.6%). Significant diffe-
rences in the occurrence of metabolic syndrome 
depending on definition were also influenced by 
glucose concentration (impaired fasting plasma 
glucose was diagnosed in 37 patients (37.7%) 
according to the NCEP-ATP III definition, and in 
70 patients (58.3%) according to the IDF defi-
nition). However, the absolute values of glucose 
did not differ (Table 2). A statistically significant 
difference was discovered in the WHR values 
(MS1: 1.005 ± 0.05 vs. MS2: 1.027 ± 0.06, p < 0.05). 
 A significantly higher concentration of HDL 
was noted in the MS2 group in comparison with the 
MS1 group (52.3 ± 12.1 mg/dl vs. 42.3 ± 12.1 mg/dl, 
p < 0.05). Triglyceride concentration in serum 
was significantly higher in the MS1 group than in 
the MS2 group (228.2 ± 122.5 mg/dl vs. 122.5 ± 
± 49.1 mg/dl, p < 0.05).
After division of groups MS1 and MS2 into 
3 subgroups according to OSAS severity — mild 
(AHI 5–15/h-1), moderate (AHI 16–30/h-1) and severe 
(AHI > 30) — it was discovered that the prevalence 
of metabolic syndrome did not depend on OSAS 
severity, irrespective of the applied MS definition 
(Fig. 2). Merely weak, clinically insignificant correla-
tions between diagnosis of metabolic syndrome and 
AHI were noted (r = 0.19 for MS1 and r = 0.21 for 
MS2, p < 0.05). The occurrence of MS1 correlated 
significantly with minimal saturation (min SaO2) and 
mean saturation during sleep (mean SaO2) (r = 0.15 
for min SaO2, r = 0.18 for mean SaO2 during sleep, 
p < 0.05). Similar dependencies were not observed in 
Figure 1. Prevalence of metabolic syndrome including the number of 
its components
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MS2; however, in this case correlation with excessive 
sleepiness measured with the use of the Epworth 
sleepiness scale (ESS) occurred (r = 0.2, p < 0.05).
Discussion
The IDF definition of metabolic syndrome 
of 2005 significantly influenced the prevalence 
of metabolic syndrome in OSAS patients. If the 
NCEP-ATP III definition of 2001 had been used, 
metabolic syndrome would not have been dia-
gnosed in 22 (12.7%) patients among the study 
subjects, and the appropriate measures would 
not have been adopted. Although we did not 
note significant strong correlations between 
degree of severity of OSAS and diagnosis of 
metabolic syndrome, a  higher prevalence of 
metabolic syndrome in the study subjects with 
OSAS (56% according to the NCEP-ATP III and 
69% according to IDF) compared to the popu-
lation of adult Poles suggests that there is some 
relation between MS and OSAS. On the grounds 
of the NATPOL III research it was estimated that 
the prevalence of metabolic syndrome in Poles 
above 18 years of age reaches 20% according to 
the criteria of the NCEP-ATP III of 2001 [22]. In 
the WOBASZ research (Polish National Mul-
ticentre Research on the Population’s Health) 
of 2005 the NCEP-ATP III criteria of 2001 were 
met by 19.5% of men and 18.6% of women, and 
according to the modified criteria of 2005, me-
tabolic syndrome was observed in 23% of men 
and 20% of women [23].
In the present paper the prevalence of MS in 
OSAS patients was 56% according to the NCEP- 
-ATP III definition and 69% according to the IDF 
definition of 2005.
Lam et al. [11] used the NCEP-ATP III defi-
nition of 2005 and they diagnosed MS in 58% of 
patients with OSAS. Sasanabe et al. [12] noted 
the presence of metabolic syndrome in 50% of 
819 examined OSAS patients. While Kono et al. 
[24] diagnosed MS (the NCEP-ATP III definition 
of 2005) in just 19% of patients with OSAS.
Figure 2. Differences in prevalence of MS1 and MS2 in mild, moderate and severe OSAS patients
Table 2. Demographic data of the study subjects 
Variables MS1 group MS2 group P 
Age (yrs) 55.2 ± 8.9 52.6 ± 8.7 ns 
Sex (M/F) 86/12 107/13 ns 
AHI (h-1) 45.7 ± 22.5 44.6 ± 22.7 ns 
Systolic BP [mm Hg] 128 ± 14 127 ± 14 ns 
Diastolic BP [mm Hg] 81 ± 10 80 ± 10 ns 
WC [cm] 112.3 ± 10.8 110.7 ± 11 ns 
WHR 1.005 ± 0.05 1.027 ± 0.06 P < 0.05 
BMI [kg/m2] 33.4 ± 8.4 32.8 ± 7.8 ns 
FPG [mg/dl] 107.2 ± 28.7 106.1 ± 27.9 ns 
HDL-C [mg/dl] 52.3 ± 12.1 42.3 ± 12.1 P < 0.05 
TG [mg/dl] 228.0 ± 122.0 122.0 ± 49.0 P < 0.05 
F — female, M — male; abbreviations in the text
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Peled et al. also noted a smaller prevalence 
of MS than in the present paper. Using the NCEP-
-ATP III definition of 2001, they discovered MS 
in 30% of examined severe OSAS patients [13]. 
However, Coughlin et al. [9] discovered MS (the 
NCEP-ATP III definition of 2001) in 87% of exa-
mined severe OSAS patients.
A higher prevalence of MS (the IDF definition 
of 2005) in OSAS patients than in the present 
paper was given by Tkacova et al. [15]: MS was 
diagnosed in 77% of patients with AHI > 30. 
Similar results based on the same definition were 
obtained by Gruber et al. [8] (74% of the study 
subjects were diagnosed with MS). Available lite-
rature does not provide thus far any comparison 
of the two definitions of MS (NCEP and IDF) in 
OSAS patients or assessment of their clinical 
usefulness.
These differences seem to be significant 
in population studies, and typically different 
prevalences of MS are obtained, depending on the 
applied definition. In the NHANES research [25] 
conducted in the USA between 1992 and 2002 
on a group of 3601 people, the occurrence of MS 
was noted in 34.5% of the studied population 
(the NCEP-ATP III definition) in comparison to 
39% (the IDF definition). In the Greek population 
[26] the presence of MS was diagnosed in 24.5% 
of the 9669 adults, according to the NCEP-ATP III 
definition in comparison to 43.4% when the IDF 
definition was applied. Mancia et al. [27] stated 
that the IDF definition is more sensitive than the 
NCEP-ATP III definition while diagnosing metabo-
lic syndrome, which allows the early introduction 
of appropriate measures.
We did not observe significant dependence 
of the occurrence of MS on the degree of severity 
of OSAS; only weak correlations between AHI 
and MS occurred. Diagnosis of MS1 correlated 
significantly but also weakly with min SaO2 and 
mean SaO2; in the case of MS2 a characteristic 
dependence on ESS was discovered.
Parts of the mentioned reports confirm the 
relation between OSAS and MS. In the study 
conducted by Peled et al. [13] the prevalence 
of MS was increasing together with severity of 
OSAS; moreover, a significant dependence of MS 
and AHI and min SaO2 was noted. In the research 
conducted by Sasanabe et al. [12] a correlation be-
tween the degree of OSAS severity and prevalence 
of MS was discovered (the Japanese definition). 
In the study carried out by Gruber et al. [8] OSAS 
was connected independently with the presence 
of metabolic syndrome, and the prevalence of MS 
(IDF 2005) was 5.9 times greater in the group of 
OSAS patients than it was in the control group. 
Kono et al. [24] discovered a significant relation 
between the occurrence of MS and AHI but not 
with min SaO2. In the study conducted by Grandi 
et al. [28] there was no significant difference in 
occurrence of MS (the NCEP-ATP III definition of 
2005) in mild, moderate or severe forms of OSAS, 
and the prevalence of MS amounted to 68.7%, 
72.2% and 68.4%, respectively. In the recently 
published study by Bonsignore et al. [29] signi-
ficant correlations of MS (the IDF definition of 
2009) and AHI were observed, but when multiple 
factor analysis was used a significant dependence 
on AHI was noted only for arterial hypertension. 
To sum up, it seems that defining metabolic 
syndrome in OSAS patients with the use of the 
IDF definition is justified by the greater sensitivi-
ty of this method, which enables more frequent 
diagnosis of MS in this group of patients. The 
relation between OSAS and MS remains unexpla-
ined and needs further thorough studies.
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